



---

**For Immediate Release**

**Contacts:** Nicole Cottrill  
615.327.7999  
[ncottrill@seig-pr.com](mailto:ncottrill@seig-pr.com)

Ms. Jean Treadwell  
905.816. 8344  
[jean.treadwell@patheon.com](mailto:jean.treadwell@patheon.com)

**Date:** November 17, 2008

## **Patheon and Senopsys Announce Alliance**

**Toronto, Canada,** – Patheon (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry and Senopsys LLC, a specialty pharmaceutical services company, have formed an alliance to develop dose formulations which enhance palatability (taste) for drugs that are in development.

The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products. These products will be optimized for palatability to increase patient compliance and improve health outcomes. Products with enhanced sensory characteristics such as smell, taste, texture, mouthfeel and appearance, ultimately can have a dramatic effect on whether a patient consistently adheres to the required dosing regimen.

Wes Wheeler, Patheon's CEO stated, "By creating this alliance with Senopsys, both companies can combine the proven history of Patheon's experience in formulation development and quality with Senopsys' expertise in taste assessment and optimization. The unique combination of innovative formulation and taste masking allows us to offer customers the potential to meet regulatory requirements and extend the patent life of their new drugs by six months."

Jeff Worthington, Senopsys' President and Founder said, "We believe this strategic alliance is of great benefit to our respective customers. Senopsys can provide Patheon with expertise in human taste panel assessment and sensory-directed taste optimization while we can utilize Patheon's global network of sites to develop customer drug products."

Senopsys uses its proprietary FlavorMetrics<sup>SM</sup> sensory assessment tools to quantitatively measure the taste masking challenge of drug substances and the palatability of drug products. Using its FlavorOpt<sup>SM</sup> Sensory Optimization System, Senopsys applies its knowledge of sensory science, taste masking, flavor construction and excipient functionality to develop palatable drug products to meet the needs of specific patient populations.

### **ABOUT PATHEON**

Patheon Inc. (TSX: PTI; [www.patheon.com](http://www.patheon.com)) is a leading provider of contract development and

manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnical companies. Patheon's technologies and services range from pre-clinical development to manufacturing a full array of dosage forms. Their global network of ten manufacturing facilities and seven development centers ensures that customer products can be launched with confidence anywhere in the world.

#### **ABOUT SENOPSYS**

Senopsys ([www.senopsys.com](http://www.senopsys.com)) is a specialty services company dedicated to the development of palatable pharmaceuticals. The company partners with pharmaceutical, biotechnology and drug delivery companies to develop patient acceptable drug products that improve patient compliance, health outcomes and drug sales. Senopsys' services include taste assessment and taste optimization of investigational and approved drugs. Senopsys uses its proprietary FlavorMetrics<sup>SM</sup> and FlavorOpt<sup>SM</sup> analytic tools to develop palatable drug products for pediatric, adult and special needs patients. Senopsys has experience with traditional dosage forms including liquids, powders, granules, chewable tablets and nasal sprays as well as novel dosage forms including fast dissolving tablets, oral films, sprays and soft chews.

#### **Caution Concerning Forward-Looking Statements**

*This news release may contain forward-looking statements which reflect management's expectations regarding the Company's future growth of operations, performance (both operational and financial) and business prospects and opportunities. These statements are made in the context of the risks and uncertainties that are outlined in the Company's public documents, which can be accessed on our website at [www.patheon.com](http://www.patheon.com) or on SEDAR at [www.sedar.com](http://www.sedar.com).*

# # #